Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Multisite Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Multisite

Protocol TAPUR
Cancer Type: Multisite
Fast Facts

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Protocol EAY131 - MATCH
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH)

Protocol EAY131 - MATCH Protocol A
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol A: EAY131-A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Protocol EAY131 - MATCH Protocol C1
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: EAY131-C1: Crizotinib in Patients with Tumors with MET Amplification

Protocol EAY131 - MATCH Protocol C2
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C2: EAY131-C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion

Protocol EAY131 - MATCH Protocol E
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol E: EAY131-E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Protocol EAY131 - MATCH Protocol J
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol J: EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ, and Non-Colorectal Cancers with HER2 Amplification

Protocol EAY131 - MATCH Protocol K2
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase II Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR Mutations or Fusions.

Protocol EAY131 - MATCH Protocol L
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol L: EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations

Protocol EAY131 - MATCH Protocol M
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol M: EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations

Protocol EAY131 - MATCH Protocol T
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol T: EAY131-T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations

Protocol EAY131 - MATCH Protocol V
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol V: EAY131-V: Phase II Study of Sunitinib in Patients with Tumors with c-Kit Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Protocol EAY131 - MATCH Protocol Z1E
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1E: EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions

Protocol EAY131 - MATCH protocol Z1F
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1F: EAY131-Z1F: Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations (PTEN Loss Allowed)

Protocol EAY131 - MATCH Protocol Z1G
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1G: EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing Result

Protocol EAY131 - MATCH protocol Z1L
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol Z1L: EAY131-Z1L: Phase II Study of BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations

Protocol EAY131 - MATCH Protocol Z1H
Cancer Type: Molecular

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol Z1H: EAY131-Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Result and PTEN Expression by IHC

Protocol SWOG S1609 DART
Cancer Type: Rare Tumors
Fast Facts

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Protocol EAY131 - MATCH Protocol Z1M
Cancer Type: Molecular
Fast Facts

Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A221602
Cancer Type: Cancer Control - Nausea
Fast Facts

Olanzapine With or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A231601CD
Cancer Type: CCDR
Fast Facts

Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol DCP-001
Cancer Type: Multisite - Screening

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAY131 - MATCH Protocol H
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol H: EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.